Magazine Article
| August 9, 2017

Alternatives To Funding Lower-Priority Trials

While some pharma companies struggle to backfill their pipelines, others find the opposite, that they have more development opportunities than they can pursue. While this may seem to be a nice problem to have — the luxury to be able to choose the very best of the very best — it also means that otherwise good drug candidates may be pushed down the list of priorities.